Breakthrough Expansion of CPT Codes for STRATA's Treatments
HORSHAM, Pa. — STRATA Skin Sciences, Inc. (“STRATA” or the “Company”) (NASDAQ: SSKN) is making headlines with its significant advancements in dermatologic care. This medical technology company is proud to announce that the American Medical Association (AMA) has accepted revisions to CPT codes 96920-96922. This historic update broadens the scope of excimer laser treatments, which are pivotal for those suffering from various inflammatory and auto-immune skin diseases.
Understanding the Implications of the CPT Code Update
Previously limited primarily to treating psoriasis, the excimer laser now has its eligibility expanded. The new code revisions reflect over two decades of robust clinical evidence supporting STRATA’s XTRAC® Excimer Lasers as safe and effective. These lasers provide an essential, non-drug option for managing chronic inflammatory skin disorders.
This update is not merely a paperwork change; it aligns with current FDA approvals and payor guidelines, effectively addressing many previous barriers to reimbursement. With its groundbreaking adjustments, STRATA anticipates a notable reduction in systemic denial instances and prior authorization requirements. This streamlined access denotes a significant leap towards enhancing patient care.
Expanded Patient Access to Critical Treatments
The revisions open doors for a staggering potential of over 30 million patients, significantly increasing the current coverage from around 10 million who are just psoriasis patients. The change is particularly crucial for individuals suffering from:
- 3 million with vitiligo
- 16.5 million with atopic dermatitis
- 4.6 million with alopecia areata
STRATA has earnestly advocated for these changes, collaborating closely with numerous dermatological experts. These efforts culminated in a formal application for changes in CPT codes that now better reflect the laser’s capabilities across various conditions.
The Role of Dermatological Experts
Key opinion leaders including Dr. Mark Lebwohl, a prominent figure in dermatology, and Dr. Pearl Grimes of the Global Vitiligo Foundation, have played vital roles in bolstering STRATA's case for expanded treatment coverage. Their insights reflect a collective understanding of the necessity for broader insurance coverage, emphasizing the laser's utility beyond psoriasis.
Positive Industry Transformations Ahead
Dr. Dolev Rafaeli, STRATA’s CEO, celebrated the milestone as a true testament to the wider clinical application of the XTRAC excimer laser. He stated, “This CPT update validates extensive data proving the utility of excimer lasers, reinforcing our commitment to improving access to effective dermatologic solutions.”
Additionally, Dr. Lebwohl noted, “This update is validating the excimer laser's broader potential, promoting greater access to effective treatments for patients.” Dr. Grimes further emphasized the potential benefits, indicating that this change allows more patients the opportunity to receive crucial therapies.
Preparing for Growth in themarket
With the CPT updates paving a clearer reimbursement path, STRATA is positioned for significant growth. Currently, non-psoriasis treatments represent about 30% of excimer laser use, and these changes are expected to spur adoption rates and elevate revenue. STRATA's XTRAC platform is utilized in over 1,400 clinics, with 4,000 providers already benefiting from its applications, indicating a ripe opportunity for expansion.
This milestone marks a pivotal turning point in the history of dermatology, one that reflects STRATA’s dedication to evidence-based practice and patient accessibility. Utilizing insights from international markets like those in China, Japan, and Korea, the efficacy of excimer lasers is clear; they offer safe alternatives to traditional drug therapies.
“With around 850 recurring revenue devices operating in the United States, expanding access to these innovative therapies can lead to dramatically increased usage,” Dr. Rafaeli concluded, highlighting the interconnected benefits for patients, providers, and payers alike.
About STRATA Skin Sciences, Inc.
STRATA Skin Sciences is committed to advancing dermatologic care. Its innovative products, including the XTRAC® excimer laser, VTRAC® lamp systems, and TheraClear® X Acne Therapy System, are designed to address a range of skin conditions from psoriasis to acne. The company encourages growth through its unique partnership program, offering a flexible fee structure that allows practices to utilize their transformative technologies without large upfront costs.
Frequently Asked Questions
What are the changes to the CPT codes announced by STRATA?
The CPT code revisions now include expanded reimbursement eligibility for excimer laser treatments, encompassing multiple inflammatory and auto-immune skin conditions, not just psoriasis.
How will these changes benefit patients?
These changes are expected to significantly increase patient access to treatments, allowing millions more to receive essential therapies for their skin conditions without burdensome pre-authorization requirements.
Who were the key contributors to this milestone?
Key contributors include dermatology experts such as Dr. Mark Lebwohl, Dr. Pearl Grimes, and Dr. Elisabeth Richard, who advocated for the change through collaboration with STRATA.
What does this mean for STRATA's business model?
The updated CPT codes are expected to enhance commercial growth and streamline the reimbursement process, potentially increasing adoption and revenue across STRATA’s offerings.
What is the importance of excimer lasers in dermatology?
Excimer lasers are vital for treating chronic inflammatory skin diseases, providing patients with effective, non-drug options that enhance healing and quality of life.
